lilly trials retatrutide A Study of (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Eli Lilly Moves Closer To

A 2021 study identified a putative beta-arrestin "superagonist" of the ghrelin receptor, showing that biased agonism at this receptor could produce functionally distinct outcomes depending on which signaling pathway is preferentially activated

Her hunger decreased significantly, and she found herself no longer fixated on snacking or late-night cravings

PubMed Fisher GJ, et al

Based on CMS' analysis and feedback provided by commenters, we believe that the Beneficiary-Pharmacy Methodology is likely more operationally complex, less accurate, and does not offer a significant improvement as a replacement for or use in conjunction with the Pharmacy-Prescriber Methodology